Are inhaled corticosteroids useful in the emergency department treatment of acute asthma?
Journal Club
Reviewer: Marcia Edmonds, MD
University of Alberta, Edmonton, Alta.
CJEM 1999;1(1):38-39
Article chosen
Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma [see comment]. Am J Respir Crit Care Med 1998;157:698-703.
Clinical bottom line
This study shows that, in patients receiving inhaled salbutamol in the emergency department (ED), the addition of high-dose flunisolide (Bronalide; Boehringer Ingelheim, Burlington, Ont.) significantly improves peak expiratory flow rate (PEFR) and forced expiratory volume in 1 minute (FEV1) compared with placebo. There was a trend toward decreased admission rate in the flunisolide group that may be clinically significant but did not achieve statistical significance. We do not know if there is an additive effect of oral or intravenous steroids. Other trials have shown conflicting results.
The search
A MEDLINE search, 1995 to 1998, using the following MeSH headings:
| 1. exp/ asthma | 8457 |
| 2. exp/ anti-inflammatories, steroidal | 16770 |
| 3. exp/ double-blind method | 13180 |
| 4. exp/ emergencies | 3325 |
| 5. 1 AND 2 AND 3 AND 4 | 3 |
The evidence
Design: Randomized, double-blind trial.
Population: Ninety-four patients aged 18 to 50 years who presented to the ED with an exacerbation of asthma (with FEV1 and PEFR £ 50% of predicted). The treatment groups were similar in all baseline demographic and clinical variables reported.
Intervention: Flunisolide 1 mg and salbutamol 400 mg q 10 min. versus salbutamol alone 400 mg q 10 min. All treatments were by multi-dose inhaler with spacer.
Outcomes measured: FEV1, PEFR, respiratory rate, heart rate, accessory-muscle use, dyspnea and wheezing were measured at 30-minute intervals for 3 hours after presentation. Side effects (nausea, palpitations, tremor, anxiety and headache) and admission rates were compared at the end of therapy.
Results: The flunisolide group had significantly better PEFR at 90, 120, 150 and 180 minutes, and better FEV1 at 120, 150 and 180 minutes than did the placebo-treated group. The difference between groups increased with time. Four flunisolide-treated patients and 12 placebo-treated patients required admission (8.5% v. 25.5%; number needed to treat [NNT] = 6). A difference of this magnitude would be clinically significant, but given the sample size, this outcome did not achieve statistical significance. Subgroup analysis showed that placebo-treated patients whose symptom duration was greater than 24 hours had significantly lower FEV1 and higher clinical scores (including dyspnea, wheezing and accessory muscle use) at 120, 150, and 180 minutes than flunisolide-treated patients (regardless of symptom duration) or placebo-treated patients with symptom duration less than 24 hours. There was no difference in adverse effects between treatment and control groups.
Comments
Study patients did not receive oral or intravenous corticosteroids, so we cannot determine whether inhaled corticosteroids have an additive effect to intravenous or oral corticosteroids. Study patients received a particularly high dose of flunisolide (6 mg/h over 3 hours; total, 18 mg). The usual dose recommended for maintenance is 1 to 2 mg/d. The cost of a flunisolide inhaler containing 25 mg (100 ¥ 250 mg) is $15. The cost of one 50-mg prednisone tablet is $0.07. Other studies have found conflicting results: Sung and colleagues1 found a trend toward improved pulmonary index score when inhaled budesonide was added to oral prednisone in acute pediatric asthma. Guttman and coworkers2 showed no effect when inhaled beclomethasone was added to intravenous methylprednisolone in adults with acute asthma. Scarfone and colleagues3 found nebulized dexamethasone was as effective as oral prednisone in the ED treatment of moderate asthma in children.
Recommendations
Current evidence does not support the routine use of inhaled steroids in all patients who present with acute asthma to the ED. However, inhaled steroid use in the ED may be beneficial in some patients. A systematic review or large, randomized controlled trial is warranted.
References
- Sung L, Osmond MH, Klassen TP. Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma. Acad Emerg Med 1998;5:209-13.
- Guttman A, Afilalo M, Colacone A, Kreisman H, Dankoff J. The effects of combined intravenous and inhaled steroids (beclomethasone dipropionate) for the emergency treatment of acute asthma. Acad Emerg Med 1997;4:100-6.
- Scarfone RJ, Loiselle JM, Wiley JF 2d, Decker JM, Henretig FM, Joffe MD. Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children. Ann Emerg Med 1995;26:480-6.
Date appraised: Dec. 15, 1998
Search
Downloads
-
61.87 KB
